Protagenic Therapeutics, Inc.\new annual ebitda
2014
2015
2016
2017
2018
2019
2020
2022
2023
2024
2026
Protagenic Therapeutics, Inc.\new EBITDA Growth & History (PTIX)
Protagenic Therapeutics, Inc.\new's calculated EBITDA was −$4.5M for fiscal 2026.
View full Protagenic Therapeutics, Inc.\new company overviewProtagenic Therapeutics, Inc.\new annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-03-31 | −$4.5M | $1.2M | — |
| 2024 | 2024-12-31 | −$5.7M | −$1.2M | — |
| 2023 | 2023-12-31 | −$4.5M | −$940,998 | — |
| 2022 | 2022-12-31 | −$3.6M | −$1.0M | — |
| 2020 | 2020-12-31 | −$2.6M | −$465,534 | — |
| 2019 | 2019-12-31 | −$2.1M | $227,989 | — |
| 2018 | 2018-12-31 | −$2.3M | $51,396 | — |
| 2017 | 2017-12-31 | −$2.4M | −$132,209 | — |
| 2016 | 2016-12-31 | −$2.2M | −$1.7M | — |
| 2015 | 2015-06-30 | −$490,000 | $485,000 | — |
| 2014 | 2014-06-30 | −$975,000 | — | — |
Protagenic Therapeutics, Inc.\new quarterly ebitda
Q2.11
Q3.11
Q2.11
Q3.11
Q3.16
Q2.16
Q3.16
Q4.16
Q1.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q3.26
Q4.26
Q1.27
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q1 2027 | 2026-06-30 | −$952,935 | $242,868 | — |
| Q4 2026 | 2026-03-31 | −$1.2M | $190,667 | — |
| Q3 2026 | 2025-12-31 | −$912,531 | −$511,130 | — |
| Q3 2025 | 2025-09-30 | −$1.1M | −$745,918 | — |
| Q2 2025 | 2025-06-30 | −$1.2M | −$886,543 | — |
| Q1 2025 | 2025-03-31 | −$1.4M | $290,251 | — |
| Q4 2024 | 2024-12-31 | −$401,401 | $784,207 | — |
| Q3 2024 | 2024-09-30 | −$355,374 | $1.1M | — |
| Q2 2024 | 2024-06-30 | −$309,260 | $834,391 | — |
| Q1 2024 | 2024-03-31 | −$1.7M | −$986,583 | — |
| Q4 2023 | 2023-12-31 | −$1.2M | −$735,729 | — |
| Q3 2023 | 2023-09-30 | −$1.4M | −$338,361 | — |
| Q2 2023 | 2023-06-30 | −$1.1M | −$654,789 | — |
| Q1 2023 | 2023-03-31 | −$739,204 | −$218,552 | — |
| Q4 2020 | 2020-12-31 | −$449,879 | $287,265 | — |
| Q3 2020 | 2020-09-30 | −$1.1M | −$902,395 | — |
| Q2 2020 | 2020-06-30 | −$488,862 | $16,318 | — |
| Q1 2020 | 2020-03-31 | −$520,652 | $133,278 | — |
| Q4 2019 | 2019-12-31 | −$737,144 | −$212,981 | — |
| Q3 2019 | 2019-09-30 | −$189,537 | $308,447 | — |
| Q2 2019 | 2019-06-30 | −$505,180 | $179,858 | — |
| Q1 2019 | 2019-03-31 | −$653,930 | −$47,335 | — |
| Q4 2018 | 2018-12-31 | −$524,163 | $132,840 | — |
| Q3 2018 | 2018-09-30 | −$497,984 | $58,137 | — |
| Q2 2018 | 2018-06-30 | −$685,038 | −$230,356 | — |
| Q1 2018 | 2018-03-31 | −$606,595 | −$110,091 | — |
| Q1 2017 | 2017-03-31 | −$657,003 | $68,657 | — |
| Q4 2016 | 2016-12-31 | −$556,121 | $4.2M | — |
| Q3 2016 · Sep 30 | 2016-09-30 | −$454,682 | $4.4M | — |
| Q2 2016 · Jun 30 | 2016-06-30 | −$496,504 | $2.8M | — |
| Q3 2016 · Mar 31 | 2016-03-31 | −$725,660 | $3.4M | — |
| Q3 2011 · Sep 30 | 2011-09-30 | −$4.8M | — | — |
| Q2 2011 · Jun 30 | 2011-06-30 | −$4.8M | — | — |
| Q3 2011 · Sep 30 | 2010-09-30 | −$3.3M | — | — |
| Q2 2011 · Jun 30 | 2010-06-30 | −$4.2M | — | — |
Protagenic Therapeutics, Inc.\new ebitda trends
Over the last five reported fiscal years, Protagenic Therapeutics, Inc.\new's ebitda decreased from −$2.1M to −$4.5M, a change of −$2.4M. The latest reported quarter, Q1 2027, shows −$952,935.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Protagenic Therapeutics, Inc.\new filings at SEC.gov ↗